Alpha Tau Medical (NASDAQ:DRTS) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Alpha Tau Medical (NASDAQ:DRTS) announced its earnings results on Monday. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02, Yahoo Finance reports.

Alpha Tau Medical Trading Down 2.2 %

DRTS stock traded down $0.06 during trading on Wednesday, reaching $2.65. 16,472 shares of the stock traded hands, compared to its average volume of 34,424. The business’s 50 day moving average price is $2.72 and its 200-day moving average price is $2.94. The firm has a market capitalization of $184.63 million, a PE ratio of -6.63 and a beta of 0.75. Alpha Tau Medical has a 52-week low of $2.15 and a 52-week high of $4.80. The company has a debt-to-equity ratio of 0.07, a current ratio of 12.07 and a quick ratio of 12.07.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Alpha Tau Medical in a research report on Wednesday.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.